Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. PAZEO OPHTHALMIC SOLUTION 0.7% [SIN15242P]

PAZEO OPHTHALMIC SOLUTION 0.7% [SIN15242P]

Active ingredients: PAZEO OPHTHALMIC SOLUTION 0.7%

Last updated 26 October 2025

On this page

Product Info
4.1 Therapeutic Indications
4.2 Posology and method of administration

Product Info

PAZEO OPHTHALMIC SOLUTION 0.7%

[SIN15242P]

Product information

Active Ingredient and Strength

OLOPATADINE HYDROCHLORIDE 0.776% EQV OLOPATADINE - 0.7%

Dosage Form

SOLUTION, STERILE

Manufacturer and Country

ALCON LABORATORIES, INC. (ASPEX) / (FORT WORTH NORTH) - UNITED STATES
S.A. ALCON-COUVREUR N.V. - BELGIUM

Registration Number

SIN15242P

Licence Holder

NOVARTIS (SINGAPORE) PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01GX09

4.1 Therapeutic Indications

PAZEO is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

4.2 Posology and method of administration

One drop in each affected eye once daily.

Pediatric Use
The safety and effectiveness has been established in pediatric patients 2 years of age and above.

Geriatric Use
No dosage regimen adjustment is required in patients 65 years of age or above.

Special populations
Olopatadine Eye Drops, Solution has not been studied in patients with renal or hepatic disease. However, no dosage adjustment is expected to be necessary in hepatic or renal impairment.

Method of administration

  • For topical ocular use only. Not for injection or oral use.

  • To avoid contamination, the dropper tip should not touch any surface. The dropper tip should also not come into contact with the eye as this may cause injury to the eye. When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.

  • The bottle should be kept tightly closed when not in use.

  • If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 5 minutes apart. Eye ointments should be administered last.

  • Patients should be advised not to wear a contact lens if their eye is red.

  • Pazeo should not be used to treat contact lens related irritation.

4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients.